View in EDS HTML Full Text PDF Full Text

Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.

Saved in:
Bibliographic Details
Title: Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
Authors: Suhrie, Kayla R. (AUTHOR), Hammers, Dustin B. (AUTHOR), Porter, Sariah M. (AUTHOR), Dixon, Ava M. (AUTHOR), King, Jace B. (AUTHOR), Anderson, Jeffrey S. (AUTHOR), Duff, Kevin (AUTHOR), Hoffman, John M. (AUTHOR)
Source: Journal of Clinical & Experimental Neuropsychology. Nov2021, Vol. 43 Issue 9, p861-878. 18p. 5 Charts, 3 Graphs.
Subjects: Amnestic mild cognitive impairment, Alzheimer's disease, Neuropsychological tests, Older people, Clinical drug trials
Abstract: Introduction: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been associated, to varying degrees, with commonly used biomarkers of Alzheimer's disease (AD). Given the ease of RBANS administration as a screening tool for clinical trials and other applications, a better understanding of how RBANS performance is associated with presence of APOE ε4 allele[s], cerebral amyloid burden, and hippocampal volume is warranted. Method: One hundred twenty-one older adults who were classified as intact, amnestic Mild Cognitive Impairment, or mild AD underwent cognitive assessment with the RBANS, genetic analysis, and quantitative brain imaging. APOE ε4 carrier status, 18F-Flutemetamol composite standardized uptake value ratio (SUVR), and hippocampal volume were each regressed on demographic variables and RBANS Total Scale score, Index scores, and subtest scores. Results: Lower RBANS Total Scale score or Delayed Memory Index (DMI) predicted the presence of APOE ε4 allele[s], higher cerebral amyloid burden, and lower hippocampal volumes. DMI was a slightly better predictor than Total Scale score for most AD biomarkers. No demographic variables consistently contributed to these models. Conclusions: The RBANS – DMI in particular – is sensitive to AD pathology. As such, it could be used as a predictive tool, particularly in clinical drug trials to enrich samples prior to less accessible AD biomarker investigation. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Clinical & Experimental Neuropsychology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 155469624
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Suhrie%2C+Kayla+R%2E%22">Suhrie, Kayla R.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hammers%2C+Dustin+B%2E%22">Hammers, Dustin B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Porter%2C+Sariah+M%2E%22">Porter, Sariah M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dixon%2C+Ava+M%2E%22">Dixon, Ava M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22King%2C+Jace+B%2E%22">King, Jace B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Anderson%2C+Jeffrey+S%2E%22">Anderson, Jeffrey S.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Duff%2C+Kevin%22">Duff, Kevin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hoffman%2C+John+M%2E%22">Hoffman, John M.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Clinical+%26+Experimental+Neuropsychology%22">Journal of Clinical & Experimental Neuropsychology</searchLink>. Nov2021, Vol. 43 Issue 9, p861-878. 18p. 5 Charts, 3 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Amnestic+mild+cognitive+impairment%22">Amnestic mild cognitive impairment</searchLink><br /><searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Neuropsychological+tests%22">Neuropsychological tests</searchLink><br /><searchLink fieldCode="DE" term="%22Older+people%22">Older people</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+drug+trials%22">Clinical drug trials</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been associated, to varying degrees, with commonly used biomarkers of Alzheimer's disease (AD). Given the ease of RBANS administration as a screening tool for clinical trials and other applications, a better understanding of how RBANS performance is associated with presence of APOE ε4 allele[s], cerebral amyloid burden, and hippocampal volume is warranted. Method: One hundred twenty-one older adults who were classified as intact, amnestic Mild Cognitive Impairment, or mild AD underwent cognitive assessment with the RBANS, genetic analysis, and quantitative brain imaging. APOE ε4 carrier status, 18F-Flutemetamol composite standardized uptake value ratio (SUVR), and hippocampal volume were each regressed on demographic variables and RBANS Total Scale score, Index scores, and subtest scores. Results: Lower RBANS Total Scale score or Delayed Memory Index (DMI) predicted the presence of APOE ε4 allele[s], higher cerebral amyloid burden, and lower hippocampal volumes. DMI was a slightly better predictor than Total Scale score for most AD biomarkers. No demographic variables consistently contributed to these models. Conclusions: The RBANS – DMI in particular – is sensitive to AD pathology. As such, it could be used as a predictive tool, particularly in clinical drug trials to enrich samples prior to less accessible AD biomarker investigation. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Clinical & Experimental Neuropsychology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=155469624
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/13803395.2021.2023476
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 18
        StartPage: 861
    Subjects:
      – SubjectFull: Amnestic mild cognitive impairment
        Type: general
      – SubjectFull: Alzheimer's disease
        Type: general
      – SubjectFull: Neuropsychological tests
        Type: general
      – SubjectFull: Older people
        Type: general
      – SubjectFull: Clinical drug trials
        Type: general
    Titles:
      – TitleFull: Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Suhrie, Kayla R.
      – PersonEntity:
          Name:
            NameFull: Hammers, Dustin B.
      – PersonEntity:
          Name:
            NameFull: Porter, Sariah M.
      – PersonEntity:
          Name:
            NameFull: Dixon, Ava M.
      – PersonEntity:
          Name:
            NameFull: King, Jace B.
      – PersonEntity:
          Name:
            NameFull: Anderson, Jeffrey S.
      – PersonEntity:
          Name:
            NameFull: Duff, Kevin
      – PersonEntity:
          Name:
            NameFull: Hoffman, John M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 13803395
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Journal of Clinical & Experimental Neuropsychology
              Type: main
ResultId 1